Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
Colorectal Cancer, Neoplasm Metastasis
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring Colorectal cancer,, immunohistochemistry,, monoclonal antibodies,, predictive model,, antiangiogenic agents,, medical imaging, Colorectal cancer with liver metastases
Eligibility Criteria
Inclusion Criteria: Patients >= 18 years old Patients with colon or rectal carcinoma histologically proven Patients with metastases (synchronous or metachronous) Patients with associated extra-hepatic disease (asymptomatic primary tumor or extra-hepatic metastases) Performance status (World Health Organization [WHO]) = 0, 1, or 2 Life expectancy >= 3 months Patients with normal haematological, kidney, and liver parameters (PNN > 1.5 x 10^9/L, platelets > 100 10^9/L, total bilirubin <= 1.25 x upper limit of normal (ULN), ASAT/ALAT <= 5 x ULN, creatinaemia <= 135 µmol/L (1.5 mg/dL) No cardiac or coronary insufficiency untreated At least 4 weeks between surgery and study beginning Patients can have a biopsy of the hepatic lesion identified by ultrasound. Informed consent signed. Exclusion Criteria: Patients with symptomatic tumors (colon or rectal) Patients with others tumors not cured Patients who cannot be treated by 5-fluorouracil (5-FU) and/or irinotecan because of special medical conditions or other serious disease. Patients who participated in another clinical trial since less than 30 days Pregnancy or breast-feeding women Patients who cannot be treated because of active infection or other serious disease.
Sites / Locations
- Jean-Alain Chayvialle
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1
2
Bevacizumab
Cetuximab